Literature DB >> 8173768

Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement.

B Crestani1, N Seta, M De Bandt, P Soler, C Rolland, M Dehoux, A Boutten, M C Dombret, E Palazzo, M F Kahn.   

Abstract

Interleukin-6 (IL-6) has been involved in the pathogenesis of inflammatory and/or autoimmune diseases. We characterized the production of IL-6 by blood monocytes and alveolar macrophages (AM) in 11 patients with definite systemic sclerosis (SSc) with lung involvement and in eight normal control subjects. IL-6 levels were determined in serum, bronchoalveolar lavage (BAL) supernatants, monocytes, and AM cell culture supernatants using an ELISA kit. BAL cell analysis evidenced an alveolitis with hypercellularity and increased neutrophils and mast cells absolute counts. Serum and BAL IL-6 levels were low and similar in SSc and control groups. The monocytes of the group with SSc secreted more IL-6 than did the control group, both spontaneously (p = 0.01) and after LPS stimulation (p = 0.0007). Spontaneous secretion of IL-6 by AM tended to be higher in the SSc group than in the control group (p = 0.22). LPS-induced IL-6 secretion by AM was similar in both groups. Our study demonstrates that during SSc lung disease, spontaneous and stimulated IL-6 secretion by blood monocytes is increased, compared with secretion by healthy control subjects. By contrast, IL-6 secretion by AM is normal despite evidence of mild alveolitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173768     DOI: 10.1164/ajrccm.149.5.8173768

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.

Authors:  Predrag Ostojic; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2006-01-27       Impact factor: 2.980

Review 2.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

3.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

4.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Authors:  Yoshihito Shima; Yusuke Kuwahara; Hiroyuki Murota; Shun Kitaba; Mari Kawai; Toru Hirano; Junsuke Arimitsu; Masashi Narazaki; Keisuke Hagihara; Atsushi Ogata; Ichiro Katayama; Ichiro Kawase; Tadamitsu Kishimoto; Toshio Tanaka
Journal:  Rheumatology (Oxford)       Date:  2010-09-05       Impact factor: 7.580

5.  Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts.

Authors:  L Gallelli; D Falcone; G Pelaia; T Renda; R Terracciano; N Malara; A Vatrella; A Sanduzzi; B D'Agostino; F Rossi; C Vancheri; R Maselli; S A Marsico; R Savino
Journal:  Cell Prolif       Date:  2008-04-24       Impact factor: 6.831

6.  Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion.

Authors:  Nila H Servaas; Barbara Mariotti; Maarten van der Kroef; Catharina G K Wichers; Aridaman Pandit; Flavia Bazzoni; Timothy R D J Radstake; Marzia Rossato
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

7.  Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.

Authors:  Mike Oliver Becker; Mislav Radic; Katrin Schmidt; Dörte Huscher; Arne Riedlinger; Marissa Michelfelder; Christian Meisel; Ralf Ewert; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

8.  Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.

Authors:  Brigitte Neuber; Jingying Dai; Wjahat A Waraich; Mohamed H S Awwad; Melanie Engelhardt; Michael Schmitt; Sergej Medenhoff; Mathias Witzens-Harig; Anthony D Ho; Hartmut Goldschmidt; Michael Hundemer
Journal:  Oncotarget       Date:  2017-10-05

Review 9.  Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.

Authors:  Yoshihito Shima
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

10.  Prediction of a Competing Endogenous RNA Co-expression Network by Comprehensive Methods in Systemic Sclerosis-Related Interstitial Lung Disease.

Authors:  Yue-Mei Yan; Ji-Na Zheng; Li-Wei Wu; Qian-Wen Rao; Qiao-Rong Yang; Di Gao; Qiang Wang
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.